Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.90 |
| ▸ | PLAU | P00749 | 2/20 | 0.90 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.90 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.69 |
| ▸ | KLK1 | P06870 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597315 | 1.00 | F2 (0.90) | F2PLAUST14PRSS1KLK1 | |
| Dibrompropamidine SCHEMBL292947 | 0.95 | F2 (1.00) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL29709297 | 0.95 | F2 (1.00) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL21083095 | 0.93 | F2 (0.97) | F2PLAUST14PRSS1 | |
| SCHEMBL22824438 | 0.93 | F2 (0.78) | F2PLAUST14PRSS1KLK1 | |
| SCHEMBL1428334 | 0.93 | F2 (0.78) | F2PLAUST14PRSS1KLK1 | |
| Dibrompropamidine SCHEMBL28086367 | 0.88 | F2 (0.85) | F2PLAUST14PRSS1 | |
| SCHEMBL16360744 | 0.87 | F2 (0.79) | F2PLAUST14PRSS1 | |
| SCHEMBL16808202 | 0.85 | F2 (0.67) | F2PLAUST14PRSS1KLK1 | |
| SCHEMBL20528835 | 0.85 | F2 (0.67) | F2PLAUST14PRSS1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | F2 3712/4885PLAU 2785/4885ST14 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.